On an acquisition trail, U.S.-based Actavis has snapped up Auden Mckenzie, a U.K. generics maker, for £306 million in cash plus royalties.
Two burning questions about Pfizer since the company backed off its ill-fated offer for AstraZeneca last May: Will the U.S.-based drug giant make another swoop at AstraZeneca? If not, who will Pfizer try to buy?
After seemingly taking forever, Sun Pharmaceuticals' $4 billion takeover of the embattled Ranbaxy Laboratories could win final approval as soon as Feb. 2 and close by mid-month. Seller Daiichi Sankyo will be glad to see it go. Sun remains cautious on the inside, more relaxed on the outside.
Everyone makes mistakes--Valeant CEO J. Michael Pearson included. And he's perfectly willing to admit it.
Welch Allyn expanded its focus on point-of-care devices with its acquisition of Hubble Telemedical, a provider of diabetic retinopathy screening in primary care settings.
Step one for incoming Takeda CEO Christophe Weber: Reorganize. Step two? Scout deals, he said Wednesday.
Actavis CEO Brent Saunders is committed to his company, its employees and the brands it sells--at least, that's the image he projected when he received Botox, the lead product from recent purchase Allergan, on a stage in front of 1,000 of the California drugmaker's sales reps.
India's medical device industry will officially open Jan. 21 to unlimited foreign direct investment as the government kicks off what is expected to be a year of vast changes in the way it regulates the products.
Back in November, Actavis said it would invite two members of Allergan's board to join the ranks of the new company's directors in the wake of their $66 billion merger. And according to Reuters ' sources, Allergan CEO David Pyott is one of them.
When GlaxoSmithKline's multibillion-dollar asset swap with Novartis closes this year, don't expect the British pharma giant to stop there, its CEO says--especially when it comes to consumer health.